List of Excipients in Branded Drug ORALONE

« Back to Dashboard

Generic Drugs Containing ORALONE

Company	Ingredient	NDC	Excipient
Sun Pharmaceutical Industries Inc	triamcinolone acetonide	51672-1335	CARBOXYMETHYLCELLULOSE SODIUM
Sun Pharmaceutical Industries Inc	triamcinolone acetonide	51672-1335	GELATIN
Sun Pharmaceutical Industries Inc	triamcinolone acetonide	51672-1335	MINERAL OIL
Sun Pharmaceutical Industries Inc	triamcinolone acetonide	51672-1335	PECTIN

What are the Most Frequently-Used Excipients in ORALONE?

# Of NDCs	Excipient
1	CARBOXYMETHYLCELLULOSE SODIUM
1	GELATIN
1	MINERAL OIL
1	PECTIN

Oralone Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Oralone is a prescription 0.1% triamcinolone acetonide dental paste used for inflammatory and ulcerative lesions of the oral mucosa. Its commercial value is driven by local retention, patient usability, and supply reliability rather than active-ingredient exclusivity. The strongest opportunities are improved mucoadhesion, lower taste burden, preservative-free stability, pediatric usability, and differentiated dosage forms.

What is Oralone and how does its formulation work?

Oralone contains triamcinolone acetonide, a synthetic corticosteroid, in an adhesive dental-paste base. The product is applied directly to oral lesions, where the formulation must remain in place despite saliva, tongue movement, swallowing, and mechanical abrasion.

The product’s performance depends on four formulation functions:

1. Maintaining drug concentration at the lesion.
2. Adhering to wet oral mucosa.
3. Releasing triamcinolone acetonide at a therapeutically useful rate.
4. Avoiding excessive irritation, unpleasant taste, or rapid washout.

The labeled inactive ingredients include gelatin, pectin, carboxymethylcellulose sodium, mineral oil, and polyethylene, according to U.S. product labeling. These components create a cohesive, water-responsive paste that adheres to mucosal tissue and forms a protective film after application (DailyMed, n.d.).

Oralone product profile

Attribute	Oralone profile
Active ingredient	Triamcinolone acetonide
Strength	0.1%
Dosage form	Dental paste
Route	Oral mucosal, topical
Regulatory status	Prescription drug
Primary use	Inflammatory and ulcerative oral mucosal lesions
Core formulation function	Mucoadhesive local delivery
Primary commercial competitors	Generic triamcinolone acetonide dental pastes, compounded oral steroid preparations, alternative topical oral corticosteroids
Biosimilar exposure	None
Main substitution risk	Generic and compounded products

What excipients are used in Oralone?

The Oralone base uses a combination of natural polymers, cellulose derivatives, and hydrophobic components.

Gelatin

Gelatin contributes film formation and cohesion. It can support adhesion after hydration, but it creates several commercial constraints:

• Animal-origin sourcing may limit use in some markets.
• Religious, dietary, and cultural requirements can affect acceptability.
• Gelatin properties can vary by source and processing.
• Moisture and temperature control are important for physical stability.
• Certain patients and institutions may prefer non-animal excipients.

A non-animal replacement could use a combination of hydroxypropyl methylcellulose, polycarbophil, carbomer, or modified starch. A replacement program would need to preserve adhesion, spreadability, drying behavior, and drug release.

Pectin

Pectin supports bioadhesion and contributes to the gel-like behavior of the hydrated paste. It is attractive for oral use because it is familiar in food and pharmaceutical applications. Its performance can vary with degree of esterification, molecular weight, pH, ionic strength, and supplier grade.

Pectin also creates a potential intellectual-property pathway. A formulation using a defined pectin grade, polymer ratio, or crosslinking condition could support composition or manufacturing claims if the resulting product demonstrates a material performance advantage.

Carboxymethylcellulose sodium

Carboxymethylcellulose sodium is a water-soluble thickener and mucoadhesive polymer. It controls viscosity, contributes to lesion coverage, and affects drug release.

Key development variables include:

• Degree of substitution.
• Viscosity grade.
• Polymer concentration.
• Particle size.
• Hydration sequence.
• Interaction with triamcinolone acetonide and the other polymers.

A high-viscosity grade may improve retention but can reduce patient acceptability and make the product difficult to extrude. A lower-viscosity system may spread more easily but wash away sooner.

Mineral oil and polyethylene

The hydrophobic portion of the base helps control water uptake and paste consistency. Mineral oil may reduce immediate dissolution and help the formulation remain cohesive in the oral cavity. Polyethylene can provide structural strength and alter the mechanical properties of the paste.

These components create a water-influenced, adhesive paste rather than a conventional aqueous gel. A reformulator should evaluate whether alternative hydrophobic materials can achieve the same persistence without increasing mouthfeel problems or interfering with drug release.

What excipient strategy offers the best commercial opportunity?

The strongest strategy is a performance-led reformulation that improves retention and patient handling while maintaining the 0.1% triamcinolone acetonide strength.

Opportunity 1: Longer-retention mucoadhesive paste

A longer-retention product could use a controlled blend of:

• Polycarbophil or carbomer.
• Hydroxypropyl methylcellulose.
• Pectin or sodium alginate.
• A hydrophobic structuring agent.
• A wetting or plasticizing system compatible with oral use.

The development target should be measurable rather than descriptive. Relevant endpoints include:

• Adhesion time on simulated buccal mucosa.
• Residence time under artificial saliva flow.
• Peel strength or detachment force.
• Drug release over two to six hours.
• Ease of application.
• Residual mouthfeel after dissolution.

A patent position would be stronger if it linked a defined polymer system to improved residence time or reduced dosing frequency. Broad claims covering “a mucoadhesive oral corticosteroid composition” would face substantial prior-art risk.

Opportunity 2: Non-animal formulation

Replacing gelatin could open additional institutional, international, and patient segments. The likely commercial claims would concern:

• Gelatin-free composition.
• Vegetarian or non-animal formulation.
• Consistent polymer sourcing.
• Improved thermal stability.
• Reduced lot-to-lot variability.

The product should not rely solely on a labeling claim. The commercial case would be stronger if the replacement also improves stability, manufacturing throughput, or patient acceptability.

Opportunity 3: Improved taste and mouthfeel

Taste is a major barrier for oral mucosal products. A commercial formulation could reduce bitterness and residual waxiness through:

• Flavor masking.
• Sweetener selection compatible with oral lesions.
• Reduced hydrophobic residue.
• Lower polymer loading.
• Microencapsulation or taste-masking of triamcinolone acetonide.
• Optimized particle size.

Flavoring agents can create regulatory and stability complications. The selected system must avoid local irritation, microbial growth, and unacceptable changes in drug release.

Opportunity 4: Unit-dose delivery

A single-use sachet, metered-dose applicator, or premeasured strip could reduce contamination and improve dosing consistency. Unit-dose packaging also creates a commercial distinction from multi-use tubes.

Potential advantages include:

• Better hygiene for recurrent oral lesions.
• More consistent amount applied.
• Improved portability.
• Lower risk of tube-tip contamination.
• Easier use in pediatric or institutional settings.

The main barriers are packaging compatibility, fill accuracy, product transfer from the container, and higher packaging cost.

Opportunity 5: Clear or translucent paste

A less visible product could improve cosmetic acceptability. A transparent or translucent hydrogel, film, or dissolving patch may be commercially attractive, but it would no longer be a simple line extension if the delivery system materially changes.

The product would require comparative work on:

• Dose uniformity.
• Adhesion to wet tissue.
• Drug release.
• Local corticosteroid exposure.
• Irritation.
• Swallowing and systemic exposure.

What formulations could compete with Oralone?

Mucoadhesive hydrogel

A hydrogel could provide easier spreading and lower mouthfeel burden. Its central weakness is rapid dilution and washout in saliva. It would need a strong polymer network or in situ gelation mechanism to compete with a paste.

Oral film or patch

A drug-loaded film can provide a measured dose and sustained contact. It may support stronger composition and manufacturing patents because the delivery architecture is more differentiated.

Commercial barriers include:

• Difficulty placing the film on irregular lesions.
• Patient comfort.
• Film flexibility and hydration.
• Residual polymer sensation.
• Risk of premature detachment.

Spray

A spray could improve access to multiple lesions and reduce direct contact with painful tissue. It would probably have shorter residence time than a paste and may create swallowing exposure. A spray product would need to demonstrate dose delivery to the lesion rather than simply oral cavity deposition.

Compounded preparations

Compounded triamcinolone acetonide oral gels and pastes can compete on price, customization, and local availability. They generally lack the same level of finished-product standardization, commercial distribution, and branded patient support as an FDA-approved product. A finished pharmaceutical product can compete by emphasizing consistent potency, validated microbial quality, standardized packaging, and documented stability.

What patents protect Oralone and its excipient platform?

The active ingredient does not provide a meaningful current exclusivity barrier. Triamcinolone acetonide is an established corticosteroid, and the core molecule has been used in approved products for decades.

The relevant IP layers are more likely to involve:

• Dental-paste composition.
• Polymer ratios.
• Drug particle-size distribution.
• Manufacturing sequence.
• Packaging and applicator design.
• Taste masking.
• Sustained-release oral films or patches.
• Specific treatment methods.
• Combination products involving anesthetics or antimicrobials.

The FDA Orange Book should be reviewed for current patent and exclusivity listings associated with the relevant Oralone product and dosage form. A marketed product may have no meaningful active Orange Book patent estate even where formulation patents exist outside the listing system or have expired (U.S. Food and Drug Administration, n.d.-a).

Patent strength by technology

Technology	Likely patent strength	Main patent vulnerability
Conventional triamcinolone dental paste	Low	Extensive prior art and predictable excipient selection
Gelatin-free paste	Low to moderate	Simple substitution may be obvious
Defined polymer ratio with improved retention	Moderate	Requires reproducible, unexpected performance data
Taste-masked triamcinolone particles	Moderate to high	Stronger if supported by dissolution and sensory data
Sustained-release oral film	Moderate to high	Delivery-system claims may be differentiated
Unit-dose applicator	Moderate	Packaging claims can be designed around
Novel in situ gelling system	Moderate to high	Depends on mechanism and clinical performance
Combination with anesthetic	Moderate	Prior-art and obviousness risk is substantial

The strongest patent strategy would combine composition claims with process and performance claims. A claim limited to a specific polymer concentration range is more defensible when the range produces a demonstrated improvement in retention, release, or stability.

When does Oralone lose exclusivity and what generic entry risks exist?

Oralone faces ordinary generic substitution risk because the active ingredient, strength, and topical oral route are established. Generic applicants could pursue an abbreviated new drug application if they can demonstrate pharmaceutical equivalence and bioequivalence through an appropriate FDA-accepted approach.

For a locally acting oral paste, the most important equivalence issues may include:

• Active-ingredient identity and strength.
• Dosage-form performance.
• Qualitative and quantitative excipient differences.
• Adhesion and residence behavior.
• Drug release.
• Product viscosity and spreadability.
• Microbial quality.
• Container-closure performance.

A generic applicant may not need to duplicate every excipient if the product meets applicable equivalence standards. That creates an opening for differentiated excipient systems, but it also means that a simple excipient change may not block generic entry.

Paragraph IV challenges

A Paragraph IV certification would be relevant only if an unexpired listed patent covered the reference product. The commercial risk depends on:

• Whether the patent is listed in the Orange Book.
• Whether the patent covers the paste, method of use, or packaging.
• The date of certification.
• Whether the sponsor files suit within the statutory period.
• Whether a 30-month stay applies.
• Whether the generic applicant uses a noninfringing formulation.

Because the core active ingredient is old, the main litigation risk would arise from formulation or method-of-use patents rather than molecule patents. No reliable assessment of a current Paragraph IV challenge should be made without the live Orange Book record and FDA litigation filings.

What is the FDA regulatory status of Oralone?

Oralone is regulated as a prescription drug for topical oral use. A reformulated product could follow different regulatory routes depending on the degree of change.

Potential regulatory pathways

Product concept	Likely regulatory route
Same strength and substantially equivalent dental paste	ANDA, if reference-product requirements are met
New delivery system with same active ingredient	505(b)(2) may be relevant
New indication or materially different dosing claim	NDA or 505(b)(2) assessment
New combination product	ANDA or 505(b)(2), depending on reference support
Compounded preparation	Pharmacy compounding framework, not an FDA-approved commercial equivalent

A 505(b)(2) strategy may be commercially useful for a film, spray, or sustained-release system that cannot satisfy conventional generic equivalence requirements. It can support reliance on existing safety information while requiring product-specific data.

Which companies are positioned to compete with Oralone?

The competitive field includes:

• The Oralone brand sponsor.
• Generic manufacturers of triamcinolone acetonide dental paste.
• Manufacturers of topical oral corticosteroid products.
• Compounding pharmacies.
• Developers of oral films, patches, gels, and sprays.
• Suppliers of mucoadhesive excipient systems.

The most credible competitors are those with established oral topical manufacturing, tube-filling capability, regulatory experience, and access to high-quality pharmaceutical polymers. Excipient suppliers with validated mucoadhesive platforms can also become licensing or co-development partners.

What licensing deals could create commercial value?

Potential licensing structures include:

1. Excipient platform license: rights to a proprietary mucoadhesive polymer blend.
2. Delivery-system license: oral film, patch, spray, or in situ gel technology.
3. Manufacturing license: specialized mixing, deaeration, filling, or unit-dose packaging process.
4. Regional commercialization license: rights outside the sponsor’s primary market.
5. Co-development agreement: shared development costs in exchange for milestone payments and royalties.

A licensor should seek claims that cover both the formulation and the manufacturing process. A license limited to a common excipient, such as carboxymethylcellulose or pectin, is unlikely to create durable value without a defined grade, ratio, or performance advantage.

How strong is the commercial opportunity for an improved Oralone formulation?

The opportunity is niche but defensible if the product solves a clear use problem. The highest-value attributes are:

• Longer mucosal residence.
• Less frequent application.
• Improved taste.
• Non-animal excipients.
• Unit-dose hygiene.
• Better application to painful or hard-to-reach lesions.
• Stable supply and consistent product texture.

Revenue exposure is difficult to quantify from public product-level data because Oralone sales are not generally reported as a standalone line item. The addressable market is constrained by the localized use of oral corticosteroids and competition from low-cost generic and compounded products.

A premium product would need a clinically meaningful or visibly superior user benefit. A minor viscosity change or excipient substitution is unlikely to justify a significant price premium.

Key Takeaways

• Oralone’s commercial differentiation depends on the dental-paste delivery system, not triamcinolone acetonide exclusivity.
• The current excipient platform combines gelatin, pectin, carboxymethylcellulose sodium, mineral oil, and polyethylene.
• The strongest reformulation opportunities are longer retention, better taste, gelatin-free composition, unit-dose packaging, and alternative delivery systems.
• Conventional paste reformulations face significant prior-art and generic-substitution risk.
• Polymer-ratio, manufacturing-process, and performance-based patents offer stronger protection than broad excipient claims.
• A 505(b)(2) pathway may be more suitable for an oral film, patch, spray, or sustained-release system than an ANDA.
• Biosimilar risk is irrelevant because Oralone contains a small-molecule corticosteroid.
• Commercial success requires measurable improvements in residence time, application, release, or patient acceptability.

FAQs About Oralone Excipient and Commercial Strategy

Can gelatin be removed from Oralone without changing the drug product?

Gelatin can potentially be replaced, but the substitute must preserve adhesion, paste cohesion, drug release, stability, and patient acceptability. A material change may require new pharmaceutical development and regulatory comparability work.

Is an Oralone oral film commercially attractive?

Yes. An oral film could provide unit dosing, longer residence, and stronger formulation differentiation. Its main risks are placement difficulty, premature detachment, mouthfeel, and the need for product-specific clinical or regulatory evidence.

Can a generic use different excipients from Oralone?

Potentially. FDA generic requirements focus on pharmaceutical equivalence and applicable bioequivalence standards, not necessarily identical inactive ingredients. Differences become more important when they affect adhesion, release, irritation, or local performance.

What excipient is best for extending oral mucosal residence time?

No single excipient is universally best. Polycarbophil, carbomer, hydroxypropyl methylcellulose, pectin, alginate, and thiolated polymers are credible candidates. Performance depends on polymer grade, concentration, hydration, saliva exposure, and formulation architecture.

Could a taste-masked Oralone product support a new patent?

Potentially. Patent strength would depend on the specific masking technology and data showing improved sensory performance without compromising stability, drug release, adhesion, or corticosteroid exposure. A generic flavor change alone would usually provide limited protection.

References

1. DailyMed. (n.d.). Oralone: Triamcinolone acetonide dental paste, 0.1%. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.-b). Abbreviated new drug application submissions: Generic drug development. https://www.fda.gov/drugs/generic-drugs

4. U.S. Food and Drug Administration. (n.d.-c). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-approval-process-drugs/505b2-applications

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.